Another study observed that preoperative chemotherapy combined with trastuzumab increased CD8+ T-cell infiltration and reduced the FoxP3+ T-cell presence compared with chemotherapy alone in HER2-positive gastric cancer, suggesting that trastuzumab may help establish a more activated, anti-tumour TIME [72]. The gene discussed is CD8A; the disease is neoplasm.